ORMALVI Trademark

Trademark Overview

On Tuesday, December 5, 2023, a trademark application was filed for ORMALVI with the United States Patent and Trademark Office. The USPTO has given the ORMALVI trademark a serial number of 98300051. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, February 11, 2025. This trademark is owned by Torrent Pharma Inc.. The ORMALVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and Medicinal preparations comprised of dichlorphenamide-based pharmaceutical products for treatment of muscle disorders
ormalvi

General Information

Serial Number98300051
Word MarkORMALVI
Filing DateTuesday, December 5, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, February 11, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 17, 2024

Trademark Statements

Goods and ServicesPharmaceutical and Medicinal preparations comprised of dichlorphenamide-based pharmaceutical products for treatment of muscle disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 5, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTorrent Pharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasking Ridge, NJ 07920
Party NameTorrent Pharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasking Ridge, NJ 07920

Trademark Events

Event DateEvent Description
Tuesday, December 5, 2023NEW APPLICATION ENTERED
Friday, March 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 3, 2024ASSIGNED TO EXAMINER
Wednesday, July 3, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 29, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, July 3, 2024NON-FINAL ACTION WRITTEN
Wednesday, July 3, 2024NON-FINAL ACTION E-MAILED
Monday, August 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 5, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 5, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 5, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 5, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 30, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, August 30, 2024FINAL REFUSAL WRITTEN
Friday, August 30, 2024FINAL REFUSAL E-MAILED
Friday, October 11, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 11, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, October 15, 2024EXAMINERS AMENDMENT -WRITTEN
Friday, October 11, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, October 15, 2024EXAMINERS AMENDMENT E-MAILED
Tuesday, October 15, 2024EXAMINER'S AMENDMENT ENTERED
Tuesday, October 15, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 15, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, December 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 17, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 17, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 11, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 18, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 18, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 18, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, February 18, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 19, 2025TEAS STATEMENT OF USE RECEIVED

Related Keywords

ormalvi pharmaceutical treatment muscle disorders products dichlorphenamide medicinal preparations comprised based